ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Subgroup Analysis of Patients With No Prior Chemo in Phase 3 EMERALD Trial: Elacestrant vs. Investigator’s Choice of Endocrine Monotherapy for ER+/HER2 mBC

57 views
June 10, 2022
Comments 0
Login to view comments. Click here to Login